Live Earnings Conference Call: AxoGen will host a live Q2 2025 earnings call on August 5, 2025 at 8:00AM ET. Follow this link to get details and listen to AxoGen's Q2 2025 earnings call when it goes live. Get details. NASDAQ:AXGN AxoGen (AXGN) Stock Price, News & Analysis $12.55 -0.12 (-0.95%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$20.00 +7.45 (+59.36%) As of 04:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AxoGen Stock (NASDAQ:AXGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AxoGen alerts:Sign Up Key Stats Today's Range$12.39▼$12.9350-Day Range$9.29▼$13.4652-Week Range$7.34▼$21.00Volume1.55 million shsAverage Volume1.47 million shsMarket Capitalization$571.53 millionP/E RatioN/ADividend YieldN/APrice Target$24.50Consensus RatingBuy Company Overview AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida. Read More AxoGen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreAXGN MarketRank™: AxoGen scored higher than 48% of companies evaluated by MarketBeat, and ranked 1123rd out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAxoGen has only been the subject of 1 research reports in the past 90 days.Read more about AxoGen's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.29) to ($0.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -83.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -83.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AxoGen's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.79% of the outstanding shares of AxoGen have been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in AxoGen has recently increased by 14.87%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.79% of the outstanding shares of AxoGen have been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in AxoGen has recently increased by 14.87%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.47 News SentimentAxoGen has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for AxoGen this week, compared to 4 articles on an average week.MarketBeat Follows3 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $224,694.00 in company stock.Percentage Held by InsidersOnly 2.78% of the stock of AxoGen is held by insiders.Percentage Held by Institutions80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AxoGen's insider trading history. Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address AXGN Stock News HeadlinesAxoGen Q2 2025 Earnings PreviewAugust 4 at 2:14 PM | msn.comAxoGen exploring possible sale after approach, Street Insider saysJuly 30, 2025 | msn.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. | Brownstone Research (Ad)Axogen gains on report of takeover interestJuly 30, 2025 | msn.comAxogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth ConferenceJuly 29, 2025 | globenewswire.comAxogen, Inc. to report 2025 second quarter financial results on August 5, 2025July 22, 2025 | globenewswire.comAxoGen’s SWOT analysis: nerve repair leader’s stock poised for growthJuly 8, 2025 | investing.comCantor Fitzgerald Reaffirms Their Buy Rating on AxoGen (AXGN)June 5, 2025 | theglobeandmail.comSee More Headlines AXGN Stock Analysis - Frequently Asked Questions How have AXGN shares performed this year? AxoGen's stock was trading at $16.48 at the beginning of 2025. Since then, AXGN shares have decreased by 23.8% and is now trading at $12.55. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) issued its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.05. The medical equipment provider had revenue of $31.20 million for the quarter, compared to analysts' expectations of $34.65 million. AxoGen had a negative net margin of 3.68% and a negative trailing twelve-month return on equity of 7.09%. Who are AxoGen's major shareholders? Top institutional shareholders of AxoGen include Assenagon Asset Management S.A. (2.25%), Y Intercept Hong Kong Ltd (0.35%), HighMark Wealth Management LLC (0.22%) and Exchange Traded Concepts LLC (0.17%). Insiders that own company stock include Karen L Zaderej, Gregory Gene Freitag, Erick Wayne Devinney, Amy Mcbride Wendell, Guido J Neels, Peter J Mariani, Michael Patrick Donovan, Joseph A Tyndall and William P Mr Burke. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that AxoGen investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings11/02/2021Today8/04/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:AXGN CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees450Year FoundedN/APrice Target and Rating Average Price Target for AxoGen$24.50 High Price Target$30.00 Low Price Target$20.00 Potential Upside/Downside+95.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.96 million Net Margins-3.68% Pretax Margin-3.68% Return on Equity-7.09% Return on Assets-3.67% Debt Debt-to-Equity Ratio0.63 Current Ratio4.28 Quick Ratio2.65 Sales & Book Value Annual Sales$187.34 million Price / Sales3.05 Cash FlowN/A Price / Cash FlowN/A Book Value$2.36 per share Price / Book5.32Miscellaneous Outstanding Shares45,540,000Free Float44,278,000Market Cap$571.53 million OptionableOptionable Beta1.00 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:AXGN) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.